FDA Approves Enhertu® for HER2-Low MBC
On August 5, 2022, the FDA approved trastuzumab deruxtecan (Enhertu®) for the treatment of people with HER2-low MBC who have received chemotherapy. This new...
Read MoreSEARCH OUR SITE
for past articles or specific information.